Evidence map›Paper›PMID 32061629›Full record

ReviewExperimental neurology2020

Transcriptional activation of antioxidant gene expression by Nrf2 protects against mitochondrial dysfunction and neuronal death associated with acute and chronic neurodegeneration.

Molly J Goodfellow, Apurva Borcar, Julie L Proctor, Tiffany Greco, Robert E Rosenthal, Gary Fiskum

Abstract readReview
In one paragraph

Review in Experimental neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Molly J GoodfellowDepartment of Anesthesiology, University of Maryland School of Medicine, United States of America.
Apurva BorcarDepartment of Anesthesiology, University of Maryland School of Medicine, United States of America.
Julie L ProctorDepartment of Anesthesiology, University of Maryland School of Medicine, United States of America.
Tiffany GrecoDepartment of Anesthesiology, University of Maryland School of Medicine, United States of America.
Robert E RosenthalDepartment of Emergency Medicine Program in Trauma, University of Maryland School of Medicine, United States of America.
Gary FiskumDepartment of Anesthesiology, University of Maryland School of Medicine, United States of America. Electronic address: gfiskum@som.umaryland.edu.

Funding

Molecular Mechanisms of Ischemia Reperfusion Brain InjuryR01NS034152 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI FISKUM, GARY M · 1995 to 2008
$2.7M
Optimal Oxygenation and Gene Expression During Critical Care after Cardiac ArrestR01NS091099 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI FISKUM, GARY M, ROSENTHAL, ROBERT EDWARD · 2015 to 2019
$2.2M
NINDS NIH HHS R01 NS034152NINDS NIH HHS R01 NS091099
6 · The paper itself

Abstract

Mitochondria are both a primary source of reactive oxygen species (ROS) and a sensitive target of oxidative stress; damage to mitochondria can result in bioenergetic dysfunction and both necrotic and apoptotic cell death. These relationships between mitochondria and cell death are particularly strong in both acute and chronic neurodegenerative disorders. ROS levels are affected by both the production of superoxide and its toxic metabolites and by antioxidant defense mechanisms. Mitochondrial antioxidant activities include superoxide dismutase 2, glutathione peroxidase and reductase, and intramitochondrial glutathione. When intracellular conditions disrupt the homeostatic balance between ROS production and detoxification, a net increase in ROS and an oxidized shift in cellular redox state ensues. Cells respond to this imbalance by increasing the expression of genes that code for proteins that protect against oxidative stress and inhibit cytotoxic oxidation of proteins, DNA, and lipids. If, however, the genomic response to mitochondrial oxidative stress is insufficient to maintain homeostasis, mitochondrial bioenergetic dysfunction and release of pro-apoptotic mitochondrial proteins into the cytosol initiate a variety of cell death pathways, ultimately resulting in potentially lethal damage to vital organs, including the brain. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a translational activating protein that enters the nucleus in response to oxidative stress, resulting in increased expression of numerous cytoprotective genes, including genes coding for mitochondrial and non-mitochondrial antioxidant proteins. Many experimental and some FDA-approved drugs promote this process. Since mitochondria are targets of ROS, it follows that protection against mitochondrial oxidative stress by the Nrf2 pathway of gene expression contributes to neuroprotection by these drugs. This document reviews the evidence that Nrf2 activation increases mitochondrial antioxidants, thereby protecting mitochondria from dysfunction and protecting neural cells from damage and death. New experimental results are provided demonstrating that post-ischemic administration of the Nrf2 activator sulforaphane protects against hippocampal neuronal death and neurologic injury in a clinically-relevant animal model of cardiac arrest and resuscitation.

Indexed as

AnimalsAntioxidantsCell DeathHumansMitochondriaNerve DegenerationNeuronsNF-E2-Related Factor 2Oxidative StressTranscriptional ActivationAntioxidantsNF-E2-Related Factor 2CalciumExcitotoxicityInflammationOxidative stressReactive nitrogen speciesReactive oxygen speciesSulforaphane

Identifiers

PMID32061629
PMCPMC8627637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.